Development of Indirect Competitive ELISA for Lithospermic Acid B of

Yu-En Shih, Chao-Hsiang Chen, Nan-Hei Lin, Jason T C Tzen

Open access · goldAbstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

1.8field-weighted citation impact, top 15% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

Nature against Diabetic Retinopathy: A Review on Antiangiogenic, Antioxidant, and Anti-Inflammatory Phytochemicals.Evidence-based complementary and alternative medicine : eCAM · 2022
Review
Activation of Nrf2 by Lithospermic Acid Ameliorates Myocardial Ischemia and Reperfusion Injury by Promoting Phosphorylation of AMP-Activated Protein KinaseFrontiers in pharmacology · 2021
Article
Development of Fluorescence In Situ Hybridization as a Rapid, Accurate Method for Detecting Coliforms in Water Samples.Biosensors · 2020
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Yu-En ShihGraduate Institute of Biotechnology, National Chung-Hsing University, Taichung 402, Taiwan. ken23710@gmail.com.

Chao-Hsiang ChenKo Da Pharmaceutical Co. Ltd., Taoyuan 324, Taiwan. gm@koda.com.tw.

Nan-Hei LinDepartment of Biotechnology and Pharmaceutical Technology, Yuanpei University of Medical Technology, Hsinchu 300, Taiwan. CMNHEI@mohw.gov.tw.

Jason T C TzenGraduate Institute of Biotechnology, National Chung-Hsing University, Taichung 402, Taiwan. tctzen@nchu.edu.tw.ORCID 0000-0002-4218-6363

National Chung Hsing University · TWTaipei Medical University · TWYuanpei University · TW

Funding

Ministry of Science and Technology MOST 104-2313-B-005 -006 -MY3 and MOST 107-2320-B-005-014

6 · The paper itself

Abstract

Lithospermic acid B (LSB), the major water-soluble ingredient of

Indexed as

Enzyme-Linked Immunosorbent AssayAntibodiesAntibody SpecificityBenzofuransCalcium-Binding ProteinsDepsidesHeart DiseasesHumansMedicine, Chinese TraditionalPlant ProteinsSalvia miltiorrhizaAntibodiesBenzofuransCalcium-Binding Proteinscaleosin protein, Sesamum indicumDepsidesPlant Proteinssalvianolic acid Bartificial oil bodiescaleosinindirection competition ELISAlithospermic acid BSalvia miltiorrhiza

Identifiers

PMID31117255

DOI10.3390/molecules24101952

PMCPMC6571667

OpenAlexW2946227755

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.